These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 37450124)
21. Advances in biomarker discovery using circulating cell-free DNA for early detection of hepatocellular carcinoma. Liu M; Zhang Z; Zhang W; Liu SM WIREs Mech Dis; 2023; 15(3):e1598. PubMed ID: 36697374 [TBL] [Abstract][Full Text] [Related]
22. Diagnosis and monitoring of virus-associated cancer using cell-free DNA. Scholte LL; Bethony JM; Xian RR Curr Opin Virol; 2023 Jun; 60():101331. PubMed ID: 37187125 [TBL] [Abstract][Full Text] [Related]
23. Size distribution of cell-free DNA in oncology. Udomruk S; Orrapin S; Pruksakorn D; Chaiyawat P Crit Rev Oncol Hematol; 2021 Oct; 166():103455. PubMed ID: 34464717 [TBL] [Abstract][Full Text] [Related]
24. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review. Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884 [TBL] [Abstract][Full Text] [Related]
25. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets. Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582 [TBL] [Abstract][Full Text] [Related]
26. Cell-Free DNA: Applications in Different Diseases. Ranucci R Methods Mol Biol; 2019; 1909():3-12. PubMed ID: 30580419 [TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma. Hu S; Liu Y; Yang Q; Chen L; Chai H; Xiao M; Qi C; Qiu W Invest New Drugs; 2023 Jun; 41(3):532-538. PubMed ID: 37099161 [TBL] [Abstract][Full Text] [Related]
28. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856 [TBL] [Abstract][Full Text] [Related]
29. Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy. Kong W; Chen T; Li Y Methods Mol Biol; 2023; 2695():127-143. PubMed ID: 37450116 [TBL] [Abstract][Full Text] [Related]
30. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related]
31. Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy. Gai W; Sun K Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634483 [TBL] [Abstract][Full Text] [Related]
32. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. Gianni C; Palleschi M; Merloni F; Di Menna G; Sirico M; Sarti S; Virga A; Ulivi P; Cecconetto L; Mariotti M; De Giorgi U Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430675 [TBL] [Abstract][Full Text] [Related]
33. Urine-Based Liquid Biopsy for Nonurological Cancers. Jain S; Lin SY; Song W; Su YH Genet Test Mol Biomarkers; 2019 Apr; 23(4):277-283. PubMed ID: 30986103 [TBL] [Abstract][Full Text] [Related]
34. Cell free DNA: revolution in molecular diagnostics - the journey so far. Nandi K; Verma R; Dawar R; Goswami B Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32083442 [TBL] [Abstract][Full Text] [Related]
35. Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. Jiang P; Chan KCA; Lo YMD J Hepatol; 2019 Aug; 71(2):409-421. PubMed ID: 31004682 [TBL] [Abstract][Full Text] [Related]
36. Cell-Free DNA, MicroRNAs, Proteins, and Peptides as Liquid Biopsy Biomarkers in Prostate Cancer and Bladder Cancer. Chen H; Xu C; Fang Z; Mao S Methods Mol Biol; 2023; 2695():165-179. PubMed ID: 37450118 [TBL] [Abstract][Full Text] [Related]
37. Cell-free DNA diagnostics: current and emerging applications in oncology. Muluhngwi P; Valdes R; Fernandez-Botran R; Burton E; Williams B; Linder MW Pharmacogenomics; 2019 Apr; 20(5):357-380. PubMed ID: 30983510 [TBL] [Abstract][Full Text] [Related]
38. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis. Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446 [TBL] [Abstract][Full Text] [Related]
39. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs. Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365 [TBL] [Abstract][Full Text] [Related]